[Dopamine-agonist resistant prolactinomas: diagnosis and management].

about

Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene.

P2860

Q42749589-8B586C18-68EB-4054-80F8-D46E253880F2

P2860

[Dopamine-agonist resistant prolactinomas: diagnosis and management].

Item

http://www.wikidata.org/entity/Q46917426

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

[Dopamine-agonist resistant prolactinomas: diagnosis and management].

@en

[Dopamine-agonist resistant prolactinomas: diagnosis and management].

@nl

type

Item

label

[Dopamine-agonist resistant prolactinomas: diagnosis and management].

@en

[Dopamine-agonist resistant prolactinomas: diagnosis and management].

@nl

prefLabel

[Dopamine-agonist resistant prolactinomas: diagnosis and management].

@en

[Dopamine-agonist resistant prolactinomas: diagnosis and management].

@nl

P1476

[Dopamine-agonist resistant prolactinomas: diagnosis and management].

@en

P2093

Nina R C Musolino

http://www.w3.org/2001/XMLSchema#string

Vanessa Q Passos

http://www.w3.org/2001/XMLSchema#string

P2860

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.

Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs.

Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.

Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease.

Current management of prolactinomas.

Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.

Functional role of estrogen in pituitary tumor pathogenesis.

Medical management of prolactin-secreting pituitary adenomas.

D2 dopaminergic receptors: normal and abnormal transduction mechanisms.

Dopamine resistance of prolactinomas.

P304

641-650

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1590/S0004-27302005000500005

http://www.w3.org/2001/XMLSchema#string

P407

Amanung Portuges

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16444347

http://www.w3.org/2001/XMLSchema#string

[Dopamine-agonist resistant prolactinomas: diagnosis and management].

about

P2860

P2860

[Dopamine-agonist resistant prolactinomas: diagnosis and management].

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698